Holen Sie sich die Stockscreener-App
234.94
0.28%
-1.03
Schlusskurs vom Vortag:
$235.97
Offen:
$236.79
24-Stunden-Volumen:
261.14K
Relative Volume:
0.37
Marktkapitalisierung:
$12.10B
Einnahmen:
$708.24M
Nettoeinkommen (Verlust:
$-188.30M
KGV:
-62.83
EPS:
-3.7392
Netto-Cashflow:
$-70.99M
1W Leistung:
+3.81%
1M Leistung:
+26.54%
6M Leistung:
+55.85%
1J Leistung:
+123.95%
1-Tages-Spanne:
$233.63
$238.56
1-Wochen-Bereich:
$224.00
$238.56
52-Wochen-Spanne:
$96.09
$238.56
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
235.11 | 12.14B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
436.35 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.49 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.00 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.23 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.84 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
New AUVELITY depression data, sleep apnea study head to ASCP 2026 - Stock Titan
Axsome Therapeutics, Inc. $AXSM Shares Acquired by Legato Capital Management LLC - MarketBeat
Axsome Therapeutics stock hits all-time high at 236.84 USD By Investing.com - Investing.com Nigeria
Axsome Therapeutics Climbs Higher On Nasdaq Momentum - Kalkine Media
Technical Reactions to AXSM Trends in Macro Strategies - Stock Traders Daily
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 1-Year HighShould You Buy? - MarketBeat
Axsome Therapeutics stock hits all-time high at 236.84 USD - Investing.com
AXSM Stock Price, Quote & Chart | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Axsome wins FDA label expansion for Auvelity in Alzheimer’s agitation - MSN
AXSM Technical Analysis | Trend, Signals & Chart Patterns | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
AXSM: June launch of new Alzheimer's agitation drug, expanded sales force, and robust pipeline progress - TradingView
Axsome Therapeutics (AXSM) price target increased by 18.66% to 272.70 - MSN
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: High Growth Potential with 18.69% Upside - DirectorsTalk Interviews
Why is Axsome (AXSM) down 6.6% since last earnings report? - MSN
Axsome projects Auvelity peak sales of at least $8B following Alzheimer's agitation approval and June launch - MSN
AXSM stock clocks best day in about 4 months on FDA greenlight for Alzheimer’s drug - MSN
Axsome Therapeutics bets on AUVELITY expansion with June Alzheimer's agitation launch - MSN
Axsome stock climbs on schizophrenia drug deal with Takeda - MSN
Axsome's Auvelity: A New Treatment For Agitation In Alzheimer's Disease (AXSM) - Seeking Alpha
AXSM Stock Chart | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Axsome Therapeutics stock hits all-time high at 234.57 USD - Investing.com India
Axsome Therapeutics stock hits all-time high at 234.57 USD By Investing.com - Investing.com Nigeria
AXSM stock is rising today after Wall Street’s positive stance despite mixed Q1 – what's behind the optimism? - MSN
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch - sharewise.com
Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $258 - Moomoo
Strong drug sales lift Axsome revenue, but profit miss drags stock - MSN
Trading the Move, Not the Narrative: (AXSM) Edition - Stock Traders Daily
White & Case advises Takeda on divestment to Axsome Therapeutics - White & Case LLP
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Understanding the 24% Potential Upside in CNS Treatments - DirectorsTalk Interviews
Axsome Q1 2026 slides: 57% revenue surge, $18B peak sales target - Investing.com Nigeria
Axsome Q1 2026 slides: 57% revenue surge, $18B peak sales target By Investing.com - Investing.com South Africa
Earnings call transcript: Axsome Therapeutics Q1 2026 reveals mixed results By Investing.com - Investing.com Australia
Earnings call transcript: Axsome Therapeutics Q1 2026 reveals mixed results - Investing.com
The week in pharma: action, reaction and insight – week to May 8, 2026 - The Pharma Letter
Axsome Therapeutics, Inc. $AXSM Holdings Decreased by State of New Jersey Common Pension Fund D - MarketBeat
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310 - Moomoo
3 Stocks Poised to Disrupt the Healthcare Market by 2030 - The Motley Fool
Principal Financial Group Inc. Lowers Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Axsome Therapeutics Inc-Aktie (AXSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
May 05 '26 |
Option Exercise |
12.95 |
233 |
3,017 |
233 |
| Jacobson Mark L. | Chief Operating Officer |
May 04 '26 |
Sale |
227.94 |
4,517 |
1,029,605 |
0 |
| Jacobson Mark L. | Chief Operating Officer |
May 05 '26 |
Sale |
228.18 |
233 |
53,166 |
0 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):